HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY3022856

targets VEGFR-3 for treatment of cancer

Also Known As:

IMC-3C5

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        LY3022856: 2
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        LY3022856: 2
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        LY3022856: 2

Experts

1.	Chiorean, E Gabriela: 1 article (10/2016)
2.	Kambhampati, Siva Rama Prasad: 1 article (10/2016)
3.	Kauh, John S: 1 article (10/2016)
4.	Knost, James A: 1 article (10/2016)
5.	O'Neil, Bert H: 1 article (10/2016)
6.	Pytowski, Bronislaw: 1 article (10/2016)
7.	Qin, Amy: 1 article (10/2016)
8.	Saif, Muhammad Wasif: 1 article (10/2016)
9.	Yu, Danni: 1 article (10/2016)
10.	Lee, Hui Mei: 1 article (01/2016)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2016 - "LY3022856 was well tolerated up to a dose of 30 mg/kg qwk, but with minimal anti-tumor activity in CRC. " 01/01/2016 - "Also, anti-lymphangiogenic drugs such as monoclonal antibodies VGX-100 and IMC-3C5 have undergone phase I clinical trials for advanced and metastatic solid tumors. " 10/01/2016 - "Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer." 10/01/2016 - "We conducted a phase 1 dose-escalation (part A) study of the VEGFR-3 human immunoglobulin G subclass 1 monoclonal antibody LY3022856 in advanced solid tumors, followed by a colorectal cancer (CRC) expansion (part B). "
2.	Colorectal Neoplasms (Colorectal Cancer) 10/01/2016 - "Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer." 10/01/2016 - "We conducted a phase 1 dose-escalation (part A) study of the VEGFR-3 human immunoglobulin G subclass 1 monoclonal antibody LY3022856 in advanced solid tumors, followed by a colorectal cancer (CRC) expansion (part B). "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)
3.	Immunoglobulin G (IgG)